Kedrion Biopharma Inc.
- UEI
- UN3DCKKLHSE7
- CAGE
- 6PRA7
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- kedrion.us
- Founded
- 2001
- Employees
- 1K-5K
- Estimated annual revenue
- $500M-$1B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | -$9,784 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Grifols USA LLC | Los Angeles, CA | 325412 Pharmaceutical Preparation Manufacturing |
| CSL Behring L.L.C. | King of Prussia, PA | 325412 Pharmaceutical Preparation Manufacturing |
| Octapharma USA Inc. | Paramus, NJ | 325414 Biological Product (except Diagnostic) Manufacturing |
| TG Therapeutics Inc. | Morrisville, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Adma Biologics, Inc. | Ramsey, NJ | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Kedrion Biopharma Inc. is a manufacturer of plasma derivatives used to treat rare and chronic conditions like hemophilia and immune deficiencies. As described on its website, the company collects and fractionates blood plasma to develop, produce, and distribute these pharmaceuticals.
Through prime federal contract awards, Kedrion Biopharma has provided specialty pharmaceutical products like RHOGAM and RHOGAM ULTRA-FILTERED PLUS to the Defense Health Agency, Department of the Army Medical Command, and Department of the Navy Bureau of Medicine and Surgery. These awards have been delivery orders issued against the GSA Pharmaceuticals and Drugs schedule contract, with no set-aside provisions applied. A $36,663 delivery order was recently issued to supply 28 packs of RHOGAM 25 to the Defense Health Agency by March 2021.
Kedrion holds a Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center for the supply of Ryplazim, a therapy for plasminogen deficiency type 1, under GSA Schedule 61-IB for Pharmaceuticals and Drugs. This single award BPA has a potential value of over $6 million through December 2024. The company also holds a multiple award Federal Supply Schedule contract for pharmaceuticals through September 2024 with the VA's Veterans Integrated Service Network 12, representing almost $24 million in potential sales. The schedule contracts and BPA provide streamlined contracting mechanisms for the VA to efficiently purchase Kedrion's specialty plasma-derived products to treat rare bleeding disorders prevalent in the veteran population.
Quick answers
Is Kedrion Biopharma Inc. registered in SAM.gov?
Kedrion Biopharma Inc.'s SAM.gov registration expired on January 2, 2025.
Which contract vehicles does Kedrion Biopharma Inc. hold?
Kedrion Biopharma Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Kedrion Biopharma Inc.'s most recent federal award?
Kedrion Biopharma Inc.'s most recent federal contract award is Rhogam ultra filtered plus (N3594920F0004), from Bureau of Medicine and Surgery (Navy), on October 1, 2020.
On GovTribe
See Kedrion Biopharma Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors